DexCom Selling And Marketing Expenses from 2010 to 2024
| DXCM Stock | USD 124.34 13.67 9.91% |
Selling And Marketing Expenses | First Reported 2010-12-31 | Previous Quarter 180.8 M | Current Value 189.8 M | Quarterly Volatility 68.7 M |
Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom main balance sheet or income statement drivers, such as Interest Expense of 15.1 M, Other Operating Expenses of 3.2 B or Operating Income of 627.6 M, as well as many exotic indicators such as Price To Sales Ratio of 23.64, Dividend Yield of 0.0 or PTB Ratio of 24.31. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.
DexCom | Selling And Marketing Expenses |
Latest DexCom's Selling And Marketing Expenses Growth Pattern
Below is the plot of the Selling And Marketing Expenses of DexCom Inc over the last few years. It is DexCom's Selling And Marketing Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DexCom's overall financial position and show how it may be relating to other accounts over time.
| Selling And Marketing Expenses | 10 Years Trend |
|
Selling And Marketing Expenses |
| Timeline |
DexCom Selling And Marketing Expenses Regression Statistics
| Arithmetic Mean | 54,496,022 | |
| Geometric Mean | 10,769,710 | |
| Coefficient Of Variation | 126.06 | |
| Mean Deviation | 57,874,652 | |
| Median | 21,900,000 | |
| Standard Deviation | 68,697,921 | |
| Sample Variance | 4719.4T | |
| Range | 189.8M | |
| R-Value | 0.89 | |
| Mean Square Error | 1090.1T | |
| R-Squared | 0.79 | |
| Significance | 0.000011 | |
| Slope | 13,614,563 | |
| Total Sum of Squares | 66071.7T |
DexCom Selling And Marketing Expenses History
About DexCom Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include DexCom income statement, its balance sheet, and the statement of cash flows. DexCom investors use historical funamental indicators, such as DexCom's Selling And Marketing Expenses, to determine how well the company is positioned to perform in the future. Although DexCom investors may use each financial statement separately, they are all related. The changes in DexCom's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on DexCom's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on DexCom Financial Statements. Understanding these patterns can help to make the right decision on long term investment in DexCom. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Selling And Marketing Expenses | 180.8 M | 189.8 M |
Pair Trading with DexCom
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.Moving against DexCom Stock
| 0.75 | DNA | Ginkgo Bioworks Holdings Financial Report 8th of May 2024 | PairCorr |
| 0.61 | IDXX | IDEXX Laboratories Financial Report 7th of May 2024 | PairCorr |
| 0.6 | GH | Guardant Health Financial Report 14th of May 2024 | PairCorr |
| 0.45 | CTSO | Cytosorbents Crp Financial Report 7th of May 2024 | PairCorr |
| 0.43 | GMED | Globus Medical Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.
The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of DexCom Correlation against competitors. Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for DexCom Stock analysis
When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.001 | Earnings Share 1.3 | Revenue Per Share 9.827 | Quarterly Revenue Growth 0.242 | Return On Assets 0.0679 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.